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Abstract
Background: Current clinical staging methods are unable to accurately define the extent of inva-
sion of localized bladder cancer, which affects the proper use of systemic therapy, surgery, and radiation.
Our purpose was to test a novel radiomics approach to identify optimal imaging biomarkers from
T2-weighted magnetic resonance imaging (MRI) scans that accurately classify localized bladder
cancer into 2 tumor stage groups (≤T2 vs >T2) at both the patient level and within bladder subsectors.
Method and Materials: Preoperative T2-weighted MRI scans of 65 consecutive patients fol-
lowed by radical cystectomy were identified. A 3-layer, shell-like volume of interest (VOI) was
defined on each MRI slice: Inner (lumen), middle (bladder wall), and outer (perivesical tissue).
An optimal biomarker method was used to identify features from 15,834 intensity and texture prop-
erties that maximized the classification of patients into ≤T2 versus >T2 groups. A leave-one-out
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strategy was used to cross-validate the performance of the identified biomarker feature set at the
patient level. The performance of the feature set was then evaluated at the subsector level of the
bladder by dividing the VOIs into 8 radial sectors.
Results: A total of 9 optimal biomarker features were derived and demonstrated a sensitivity, speci-
ficity, accuracy of prediction, and area under a receiver operating characteristic curve of 0.742, 0.824,
0.785, and 0.806, respectively, at the patient level and 0.681, 0.788, 0.763, and 0.813, respec-
tively, at the radial sector level. All 9 selected features were extracted from the middle shell of the
VOI and based on texture properties.
Conclusions: An approach to select a small, highly independent feature set that is derived from
T2-weighted MRI scans that separate patients with bladder cancer into ≤T2 versus >T2 groups at
both the patient level and within subsectors of the bladder has been developed and tested. With
external validation, this radiomics approach could improve the clinical staging of bladder cancer
and optimize therapeutic management.
© 2018 The Author(s). Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
In the United States, an estimated 79,030 new cases of
bladder cancer (60,490 men and 18,540 women) were di-
agnosed in 2017 and approximately 16,870 patients died
of the disease.1 For patients with localized bladder cancer,
the major determinants of treatment are the presumed extent
of invasion of the bladder primary tumor and its location
within the bladder. If a primary tumor is known not to have
invaded beyond the muscular wall (stage ≤T2), a patient
may be treated adequately with bladder-directed thera-
pies alone. However, if a primary tumor invades beyond
the muscle wall (ie, extra-vesicle invasion or stage >T2),
the patient requires more intensive systemic therapies and
may benefit from pelvic lymph-node directed therapy.2
In addition, recent clinical protocols suggest that boost
doses of radiation are directed only to subsectors of the
bladder that likely harbor residual disease.3 Unfortu-
nately, the appropriate treatment of bladder cancer is limited
by an inability to accurately determine both the extent of
invasion and the location of tumors within the bladder pre-
operatively. With the present evaluation methods, a patient
who is diagnosed with clinical T2 disease (ie, invasion into
the muscle but not beyond) is almost equally likely to harbor
pathologic pT0-1, pT2, pT3, or pT4 stage disease, which
is determined after cystectomy.4 Similarly, approximately
30% of patients with clinically negative pelvic lymph nodes
are found to have pathologically positive pelvic lymph nodes
after surgical dissection.
Although pelvic node involvement is strongly corre-
lated with postoperatively determined T stage, there is almost
no correlation with preoperative T stage.4 There is also a
stark discordance between the pre- and post-operative lo-
calization of tumors within subsites of the bladder.
Approximately half of patients with cystectomy will harbor
invasive tumors in subsites of the bladder that appeared free
of disease preoperatively.5 Overall, inadequate staging limits
rational treatment planning and leads to the overtreat-
ment of some patients and undertreatment of others.
In current practice, cystoscopy, tissue analysis from the
transurethral resection of the bladder tumor, pelvic com-
puted tomography (CT), and magnetic resonance imaging
(MRI) are the primary modalities used to clinically stage
patients with bladder cancer.6 MRI is the most promising
imaging method and has been shown to be sensitive to and
specific for the detection and localization of macroscopic
disease.7-21 However, current MRI techniques are not able
to detect microscopic tumor sites and qualitatively differ-
entiate reactive changes after transurethral resection from
sites of residual tumor.22-30
We undertook this study with the goal to develop an
MRI-based radiomics algorithm that may be used to improve
clinical staging and guide treatment. To our knowledge,
quantitative image analysis to better predict the extent of
invasion and location of bladder cancer from MRI scans
has not been performed previously. We hypothesized that
a quantitative image analysis with an optimal biomarker
approach on the basis of features that are extracted from
T2-weighted MRI scans can accurately classify ≤T2 versus




This retrospective study was approved by the institu-
tional review board at our institution. Pelvic axial, T2-
weighted, fast-spin, echo MRI data sets without gross motion
artifacts acquired on 1.5 to 3.0 Tesla clinical MRI scan-
ners from 65 consecutive adult patients with bladder cancer
who underwent a cystectomy and histopathologic assess-
ment (47 men, 18 women; mean age 65.6 ± 10.5 years)
between 2009 and 2015 were utilized for this study. The
image sizes varied from 268 × 208 to 512 × 448 with 23
to 65 slices and the voxel sizes varied from
0.62 × 0.62 × 4 mm3 to 1.48 × 1.48 × 12 mm3. The repeti-
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tion time ranged from 1000 msec to 6680 msec and the echo
time from 80 mse to 93 msec.
Among a total of 65 patients, 4 patients were imaged
prior to transurethral resection of bladder tumor (TURBT),
27 patients were imaged after TURBT but prior to che-
motherapy treatment, and 34 patients were imaged after
TURBT and chemotherapy. A reference standard T-stage
for each radial sector and each patient was determined by
a board-certified radiologist (DAT) on the basis of a quali-
tative assessment of the T2-weighted MRI scans and use
of available histopathology data from cystectomy specimens.
At the patient level, 31 patients were assigned to group
1 (stage ≤T2 with primary tumor that was locally con-
fined to the bladder) and 34 patients to group 2 (stage >T2
with primary tumor that was locally extending beyond the
bladder). In particular, 10 patients were stage T0, 3 pa-
tients stage Ta, 5 patients stage Tis, 5 patients stage T1, 8
patients stage T2, 24 patients stage T3 (16 patients T3a and
8 patients T3b), and 10 patients stage T4 (7 patients T4a
and 3 patients T4b) on the basis of a histopathologic as-
sessment after cystectomy.
At the sector level (where each patient study was divided
into 8 equal sectors), 401 sectors were assigned to group
1 and 119 sectors to group 2. In particular, 289 sectors
were stage T0, 3 sectors stage Ta, 18 sectors stage Tis, 29
sectors stage T1, 62 sectors stage T2, 88 sectors stage T3
(52 sectors T3a and 36 sectors T3b), and 31 sectors stage
T4 (17 sectors T4a and 14 sectors T4b).
Three-dimensional region of interest placement
and image intensity standardization
All image data sets were trimmed in a consistent manner
for body region of interest (ROI) by using a computer-
assisted visualization and analysis software system.31 The
axial slice with the maximal cross-sectional coverage through
the femoral heads was selected. An ROI rectangular box
in 3 dimensions was specified along the lateral edges of
the femoral heads and anterior and posterior boundaries of
the pelvic wall skeletal musculature.
Subseqwuently, all axial slices through the pelvis were
trimmed by the same ROI. The two axial slices within
10 mm of the superior and inferior aspects of the urinary
bladder were selected as the superior and inferior bound-
aries of the ROI, respectively. To ensure the same tissue-
specific, numeric meaning for image voxel intensity values,
all images were first corrected for intensity nonuniformities
and then standardized32-34 in accordance with a standard in-
tensity scale. The parameters of the scale were estimated
from 10 control (normal) MRI data sets.
Three-layer, shell-like volume of interest and
radial sector placement
The visual appearance and image content of urine within
the bladder lumen, bladder wall including the tumor sites,
and perivesical fat on T2-weighted MRI scans are differ-
ent as shown in Figure 1a. We postulated that the differential
features that were extracted from these different regions can
be utilized to determine bladder cancer T stage.
To classify patients into the 2 T-stage groups, a 3-layer
shell-like volume of interest (VOI) was placed about the
urinary bladder as shown in Figures 1b and 2. This in-
cludes an inner shell (containing high T2-weighted signal
intensity urine within the bladder lumen), a middle shell
(containing low-signal intensity bladder wall that is pre-
dominantly comprised of detrusor muscle and slightly
higher-signal intensity foci of bladder tumor), and an outer
shell (containing high-signal intensity perivesical fat that
extends up to 10 mm out from the outer aspect of the bladder
wall). The inner and outer boundaries of the bladder wall
were manually drawn using a computer-assisted visualiza-
tion and analysis software system on axial T2-weighted MRI
scans by 2 trained individuals (JC, SV) so that the 3 shells
could be created.
After creating the shells, we further divided each shell
automatically into 8 equally spaced radial sectors (S1-S8)
as shown in Figure 2. This figure also shows an example
of the 3-layer, shell-like structure and radial sectors that











Figure 1 (a) The Visual appearance of bladder wall (arrows) on T2-weighted magnetic resonance imaging scan. (b) Schematic diagram
of 3-layer, shell-like structure including boundaries and 8 radial sectors.
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bladder in 1 patient that covered the full extent of the VOI
(6 slices) as specified for this patient. This enabled a com-
parison of the proposed approach for bladder cancer
T-staging at both the patient and radial-sector levels. The
sector-level analysis was carried out in the 3-dimensional
sector. For illustration in Figure 2, the first 3-dimensional
sector that corresponds to S1 is comprised of the
2-dimensional, wedge-shaped regions that are labeled S1
from the 6 slices stacked together. Thus, each patient data
set yielded 8 3-dimensional sectors. Of note, each
3-dimensional sector itself consisted of 3 shells.
Feature extraction, optimal biomarker selection,
and cross-validation
A variety of image-based features including intensity and
texture properties were extracted from each radial sector
and each shell for all patients. The texture information in-
cluded the local binary pattern (LBP) and those derived from
gray level cooccurrence matrix (GLCM).35 From GLCM,
we used 6 texture properties including energy, maximum
probability, contrast, inverse difference moment, and
correlation.36 Four different versions of LBP features were
computed including the original LBP,37 median LBP,38
uniform LBP,39 and neighbor-intensity LBP.40
After the intensity and texture feature sets were ex-
tracted for the 3 shells at the patient and sector levels, a
recently developed optimal biomarker approach was used
to extract a small optimal feature set.41 The idea behind this
approach was to find a small set of discriminating fea-
tures from the set of all features in several steps as follows:
1) Extract a subset of features that have a low level of cor-
relation among all features. A heat map visualization
technique that allows for the grouping of parameters on the
basis of correlations among them was used for this purpose;
2) independently of step 1, extract a subset of features from
the entire set that is capable of separating the 2 patient groups
of interest. Each feature is tested on its own for ability to
separate groups by using t tests; and 3) find the intersec-
tion of these 2 subsets to generate the final small feature
set.
The accuracy of the selected features to perform a clas-
sification of the new images into the 2 classification groups
was tested with a leave-one-out strategy. A support vector
machine was used as the classifying engine. Testing data
sets in the leave-one-out strategy has no intersection with
the training data sets that are used for optimal feature se-
lection and support vector machine classification. Sensitivity,
specificity, accuracy of prediction, and area under the re-
ceiver operating characteristic (ROC) curve were computed
to describe the predictive performance of the optimal feature
sets that consisted of different numbers of optimal features.
Results
Feature selection and classification
Each patient had 3 shells, each of which was further
divided into 8 sectors for a total of 24 sectors per patient.
Each sector yielded 42 intensity properties, 672 LBP texture
properties, and 15,120 GLCM texture properties for a total
of 15,834 features per sector. Figure 3 shows the correla-
tions among all features using the heat map visualization
technique. Vertical features in the red box include
cooccurrence, matrix-based, texture features for the middle
shell of sector 2. The horizontal features in the red box
include cooccurrence, matrix-based, texture features for the
inner shell of sector 2. Features from the middle shell of
sector 2 do not much correlate with those from its inner
shell.
The size of the selected optimal feature set can be varied








Figure 2 Three-layer, shell-like structure and 8 radial sectors placed about the bladder on serial T2-weighted magnetic resonance imaging
scan in representative patient.
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the percent of top highly uncorrelated features we desire
to select for this residual correlation.41 The optimal biomarker
feature sets from a minimum of 9 features to a maximum
of 18 features were selected in this manner and analyzed.
Table 1 shows the optimal biomarker feature set with 9,
14, and 18 features and the corresponding performance mea-
sures of sensitivity, specificity, prediction accuracy, and area
under the ROC curve at both the patient and sector levels.
Figure 4 shows ROC curves at the sector and patient levels
for the 3 optimal feature sets. The best classification ac-
curacy was produced by using 9 optimal features at both
the sector and patient levels (Table 2).
Discussion
Classifying extent of invasion is crucial for
treatment planning
The inability to accurately determine the extent of in-
vasion of bladder cancer and its locations within the bladder
with routine clinical staging methods affects appropriate
treatment planning and may lead to the overtreatment of
some patients and undertreatment of others. In this study,
we focused on the binary classification of the presence or
absence of extra-vesicle invasion because this distinction
has been shown to be a strong predictor of occult pelvic
lymph node involvement,4 pelvic failure after surgery,5
disease-free survival, and overall survival.42 The accurate
classification of extra-vesicle invasion could help clini-
cians make more prudent decisions with regard to the
treatment of patients with neoadjuvant chemotherapy,
chemoradiation, cystectomy, and pelvic lymph node
dissection.
Figure 3 Heat map of feature correlation matrix.
Table 1 Classification performance for bladder cancer T-staging on the basis of T2-weighted magnetic resonance imaging scan at sector
and patient levels
Sector level Patient level
No. of features SEN SPE ACC AUC SEN SPE ACC AUC
9 0.681 0.788 0.763 0.813 0.742 0.824 0.785 0.806
14 0.790 0.748 0.758 0.816 0.742 0.765 0.754 0.798
18 0.782 0.728 0.740 0.818 0.806 0.735 0.769 0.793
ACC, accuracy of prediction; AUC, area under receiver operating characteristic curve; SEN, sensivitity; SPE, specificity.
Figure 4 Receiver operating characteristic curves to classify bladder cancer at sector level (left) and patient level (right).
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We used an optimal biomarker approach to identify fea-
tures that were extracted from T2-weighted MRI scans that
can classify extra-vesicle invasion both at the patient level
and within subsectors of the bladder. With a 64-patient train-
ing set and using features from T2-weigthed MRI sequences
alone, our algorithm demonstrated a sensitivity, specific-
ity, accuracy of prediction, and area under ROC curve of
0.742, 0.824, 0.785, and 0.806, respectively, at the patient
level and 0.681, 0.788, 0.763, and 0.813, respectively, at
the radial sector level.
To our knowledge, this is the first study of its kind to
assess the clinical staging of bladder cancer using MRI fea-
tures and our findings set a benchmark for an MRI-based
radiomics classification of the extent of invasion of bladder
cancer. Prior work indicates that the performance of tra-
ditional imaging methods in staging bladder cancer is subpar.
CT and MRI have been shown to be inaccurate in up to
50% of cases.21-23 TURBT also understages tumors in up
to 50% of patients.24-30
A limitation of our classification algorithm is that it does
not make more granular distinctions with respect to the
extent of invasion other than extra-vesicle invasion versus
no extra-vesicle invasion. More granular distinctions are im-
portant as, for example, patients with superficial invasion
alone (ie, T1) can be effectively treated with less rigorous
therapy than those with invasion into the muscle and beyond.
Another example is the subset of patients who may be cured
with diagnostic TURBT alone (T0). Although the present
analysis did not attempt to delineate more granular stages,
the analytic approach that was used in this study could natu-
rally extend to these other clinically important classification
stages in future studies.
Optimal biomarker approach allows for clinically
driven radiomics
In this study, we created a 3-layer, shell-like VOI around
the bladder and generated a feature set for each shell on
T2-weighted MRI scans. We designed and computed a large
collection of features and extracted a small subset of this
collection using an optimal biomarker approach, which
maximizes feature independence and classification
potential.41
Deep learning is an alternative approach and has been
utilized in bladder cancer segmentation and treatment-
response assessment from CT images.43-45 Deep learning
is similar to the optimal biomarker approach because a large
number of features are examined by the network depend-
ing on the needs and characteristics of the training data sets
for the classification or prediction problem43 but these fea-
tures are designed by the network and not the user. The
advantage of the optimal biomarker method is that this
method can reduce the dimensionality of the feature set while
keeping the original meaning of the features so all se-
lected features can be explained and repeatedly computed.
In contrast, it is hard to finally determine quantita-
tively what physical features (as those listed in Table 2)
are actually utilized by the network in deep learning to make
its decision. This may hinder the process of potentially study-
ing cancer pathophysiology utilizing the physical meaning
of the selected features.
Magnetic resonance imaging is a promising
modality for further development
Recent research on bladder cancer staging from CT
images reported that the use of morphological and texture
features and machine-learning techniques to stratify bladder
cancer into stage categories shos the promise of feature se-
lection and classification to predict bladder cancer status
from medical imaging.46,47 Positron emission tomography
and CT images have also been studied recently with respect
to the classification of bladder primaries but with mixed
results compared with CT and MRI-based approaches.48,49
However, in our view, MRI has important advantages
over CT-based modalities. First, MRI does not expose pa-
tients to ionizing radiation; thus, numerous sequences can
be performed without concern for late effects from radia-
tion exposure. Second, each sequence can potentially provide
additional anatomic and biologic information that can further
improve the accuracy of classification algorithms. In this
study, we considered only T2-weighted sequences. Our
results would likely improve when information from the
T2-weighted scans were combined with T1-weighted, dif-
fusion, and other biologically meaningful sequences. Future
research can extend this initial work in this direction.
Our study has certain limitations. Most notably, the clas-
sification algorithms developed herein were trained on a
Table 2 Optimal biomarker set with 9 selected features ex-
tracted from middle shell and constituting texture properties
1 Kurtosis from uniform LBP with radius 3 and
neighborhood 8
2 Kurtosis from uniform LBP with radius 3 and neighborhood
12
3 Median from contrast GLCM with window size 3x3 at 360°
angle, bins 5, and radius 3
4 Median from contrast GLCM with window size 5x5 at 360°
angle, bins 5, and radius 3
5 High quartile from correlation GLCM with window size 7x7
at 270° angle, bins 5, and radius 2
6 High quartile from contrast GLCM with window size 3x3 at
45° angle, bins 5, and radius 3
7 High quartile from contrast GLCM with window size 5x5 at
45° angle, bins 5, and radius 3
8 High quartile from correlation GLCM with window size 7x7
at 270° angle, bins 5, and radius 3
9 High quartile from contrast GLCM with window size 5x5 at
45° angle, bins 10, and radius 3
GLCM, grey level cooccurrence matrix; LBP, local binary pattern.
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small number of samples and have not been externally vali-
dated. Although the performance of these algorithms is very
promising, there is a chance that they have overfitted the
training data. As a next step in this research, we plan to
assess performance in additional patients from our own in-
stitution as well as from other institutions.
Conclusions
This is the first study to demonstrate a highly accurate
classification of extra-vesicle invasion using an optimal
biomarker approach on features that were extracted from
T2-weighted MRI scans. The derived features performed
well at both the patient level and within subsectors of the
bladder. The methods used herein have the potential to be
extended and incorporate information from additional MRI
sequences and address other clinically important classifi-
cation problems in bladder cancer.
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